Tissue distribution and antithrombotic activity of unlabeled or 14C- labeled porcine intestinal mucosal heparin following administration to rats by the oral route

Canadian Journal of Physiology and Pharmacology

Volumn 78, Issue 4, 2000, Pages 307-320

  Hiebert, Linda M ^a   Wice, Sandra M ^a   Ping, Tilly ^a   Hileman, Ronald E ^b   Capila, Ishan ^b   Linhardt, Robert J ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Distribution; Heparin; Oral administration; Radiolabel; Thrombosis; 14C heparin

Indexed keywords

GELATIN; HEPARIN;

ACETYLATION; AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; DRUG BLOOD LEVEL; INTESTINE TRANSIT TIME; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS; TISSUE DISTRIBUTION;

EID: 0034107857     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y99-140     Document Type: Article

References (69)

1. Al-Hakim, A., and Linhardt, R.J. 1990. Isolation and recovery of acidic oligosaccharides from polyacrylamide gels by semi-dry electrotransfer. Electrophoresis, 11: 23-28.
2. Altman, P.L., and Ditmer, D.S. 1964. Biology data book. Federation of American Societies for Experimental Biology, Washington, D.C. p. 264.
3. Ashwin, J.G., and Jaques, L.B. 1961. The effect of phosphorous 32, dextran, reserpine, and stypturon on thrombus formation in rats. Thromb Diath Haemorrh. 5: 543-552.
4. Asplund, J., Borell, U., and Holgrem, H. 1939. Investigations on the storage of heparin in the animal organism as well as on the possibility of its resorption in the intestine and placenta. Anat. Ann. Mikrosk. Anat. Forsch. 46: 16-67.
5. Bagasra, O., and Lischner, H.W. 1988. Activity of dextran sulphate and other polyanionic polysaccharides against human immunodeficiency virus. J. Infect. Dis. 158: 1084-1087.
6. Barzu, T., van Rijn, J.L.M.L., Petitou, M., Tobelem, G., and Caen, J.P. 1987. Heparin degradation in endothelial cells. Thromb. Res. 47: 601-609.
7. Baughman, R.A., Kapoor, S.C., Agarwal, R.K., Kisicki, J., Catella-Lawson, F., and Fitzgerald, G.A. 1998. Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans. Circulation, 98: 1610-1615.
8. Beijering, R.J., Ten Cate, H., and Ten Cate, J.W. 1996. Clinical applications of new antithrombotic agents. Ann. Hematol. 72: 177-183.
9. Berkowitz, S.D., Kosutic, G., Marder, V.J., Kanarek, B.B., and Baughman, R.A. 1999. Heparin administered orally via a novel carrier system (SNAC) is comparable to sc heparin when used to prevent venous thromboembolic events following elective total hip arthroplasty (THA). Thrombosis and Haemostasis, Suppl. Abstracts, XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington, D.C., August 14-21, 1999, p. 492.
10. Blake, O.R., Ashwin, J.G., and Jaques, L.B. 1959. An assay for the antithrombotic activity of anticoagulants. J. Clin. Pathol. 12: 118-122.
11. Chen, Y., Maguire, J., Hileman, R.E., Fromm, J.R., Esko, J.D., Lindhardt, R.J., and Marks, R.M. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3: 866-871.
12. Dawes, J., and Pepper, D. 1992. Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb. Haemostasis, 67(4): 468-472.
13. Desai, U.R., and Linhardt, R.J. 1995. Molecular weight of heparin using 13C nuclear magnetic resonance spectroscopy. J. Pharm. Sci. 84: 212-215.
14. Desai, U.R., Wang, H., Kelly, T., and Linhardt, R. 1993a. Structure elucidation of a novel acidic tetrasaccharide and hexasaccharide derived from chemically modified heparin. Carbohydr. Res. 241: 249-259.
15. Desai, U.R., Wang, H., and Linhardt, R.J. 1993b. Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochemistry, 32: 8140-8145.
16. Edens, R.E., Alhakim, A., Weiler, J.M., Rethwisch, D.G., Fareed, J., and Linhardt, R.J. 1992. Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J. Pharm. Sci. 81(8): 823-827.
17. Emmanuele, R.M., and Fareed, J. 1987. Effects of molecular weight on the bioavailability of heparin. Thromb. Res. 48: 591-596.
18. Engelberg, H. 1995. Orally ingested heparin is absorbed in humans. Clin. Appl. Thrombosis/Hemostasis, 1: 283-285.
19. Engelberg, H. 1996. Actions of heparin in the atherosclerotic process. Pharmacol. Rev. 48: 327-352.
20. Gibaldi, M., and Feldman, S. 1970. Mechanisms of surfactant effects on drug absorption. J. Pharm. Sci. 59(5): 579-589.
21. Glimelius, B., Busch, C., and Hook, M. 1978. Binding of heparin on the surface of cultured human endothelial cells. Thromb. Res. 12: 773-782.
22. Gonze, M.D., Manord, J.D., Leone-Bay, A., Baughman, R.D., Garrard, C.L., Sternbergh, W.C., and Money, S.R. 1998. Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg. 176: 176-179.
23. Guarini, S., and Ferrari, W. 1983. Sodium deoxycholate promotes the absorption of heparin administered orally, probably by acting on gastro-intestinal mucosa in rats. Experientia, 41: 350-352.
24. Hatton, M.W.C., Berry, L.R., Machovich, R., and Regoeczi, E. 1980. Tritiation of commercial heparins by reaction with NaB3H4: chemical analysis and biological properties of product. Anal. Biochem. 106: 417-426.
25. Hiebert, L.M. 1979. Heparin and endothelium. In Heparin, structure, cellular functions and clinical applications. Edited by N.M. McDuffie. Academic Press, New York. pp. 289-297.
26. Hiebert, L.M. 1981. The uptake of heparin by liver sinusoidal cells in normal and atherosclerotic rabbits. Thromb. Res. 21: 383-390.
27. Hiebert, L.M., and Jaques, L.B. 1976. Heparin uptake on endothelium. Artery, 2: 26-37.
28. Hiebert, L.M., and Wice, S.M. 1997. Oral heparin is absorbed via the stomach. FASEB J. 11(3): A314.
29. Hiebert, L.M., Wice, S.M., McDuffie, N.M., and Jaques, L.B. 1993. The heparin target organ - the endothelium. Studies in a rat model. Q. J. Med. 86: 341-348.
30. Hiebert, L.M., Wice, S.M., and Jaques, L.B. 1996. The antithrombotic activity of oral unfractionated heparin. Cardiovasc. Pharmacol. 28: 26-29.
31. Hiebert, L.M., Wice, S.M., Jaques, L.B., Williams, K.E., and Conly, J.M. 1999. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J. Lab. Clin. Med. 133: 161-170.
32. Imiela, J., Nosarzewski, J., and Gorski, A. 1995. Oral heparins in the treatment of rheumatoid arthritis. Arch. Immun. Ther. Exp. 43: 313-315.
33. Jacobsson, I., Hook, M., Peterson, I., Lindahl, U., Larm, O., Wiren, E., and Van Figura, K. 1979. Identification of N sulphated disaccharide units in heparin-like polysaccharides. Biochem. J. 179: 77-87.
34. Jandik, K.A., Kruep, D., Cartier, M., and Linhardt, R.J. 1996. Accelerated stability studies of heparin. J. Pharm. Sci. 85: 45-51.
35. Jaques, L.B. 1963. The chemistry, pharmacology and assay of heparin. Thromb. Diath. Haemorrh. 9(Suppl. 2): 27-36.
36. Jaques, L.B. 1977. Determination of heparin and related sulfated mucopolysaccharides. Methods Biochem. Anal. 24: 203-212.
37. Jaques, L.B., Wice, S.M., and Hiebert, L.M. 1990. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. J. Lab. Clin. Med. 115: 422-432.
38. Jaques, L.B., Hiebert, L.M., and Wice, S.M. 1991. Evidence from endothelium of gastric absorption of heparin and of dextran sulphates 8000. J. Lab. Clin. Med. 117: 122-130.
39. Kazatchkine, M.D., Fearon, D.T., Metcalfe, D.D., Rosenberg, R.D., Kosakai, M., and Yosizawa, Z. 1979. Stability of ester sulfates in heparin and dilute acid treatment. J. Biochem. 86: 147-153.
40. Keele, C.A., and Neil, E. 1971. Samson Wright's applied physiology. Oxford University Press, London. p. 78.
41. Larsen, A.K., Lund, D.P., Langer, R., and Folkman, J. 1986a. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc. Natl. Acad. Sci. U.S.A. 83: 2964-2968.
42. Larsen, A.K., Newberne, P.M., and Langer, R. 1986b. Comparative studies of heparin and heparin fragments: distribution and toxicity in rats. Fund. Appl. Toxicol. 7: 86-93.
43. Levy, P., and Petracek, J. 1962. Chemical and pharmacological studies on N-resulfated heparin. Proc. Soc. Exp. Biol. Med. 109: 901-905.
44. Lindahl, U., Lidholt, K., Spillmann, D., and Kjellen, L. 1994. More to heparin than anticoagulation. Thromb. Res. 75: 1-32.
45. Linhardt, R.J. 1992. Chemical and enzymatic methods for depolymerization and modification of heparin. In Carbohydrates - synthetic methods and applications in medicinal chemistry. Edited by H. Ogura, A. Hasegawa, and T. Suami. Kodansha/VCH, Tokyo/Weinheim. pp. 385-401.
46. Linhardt, R.J., Toida, T., Smith, A.E., and Hileman, R.E. 1997. Analysis of the structure of heparin and heparan sulfate by high resolution separation of oligosaccharides. In A laboratory guide to glycoconjugate analysis. Edited by J.T. Gallagher and P. Jackson. Birkhauser Verlag AG, Basel. pp. 183-197.
47. Lloyd, A.G., Fowler, L.J., and Law, B.A. 1968. Degradation of [35S]heparin by mammalian and bacterial sulfaminidases. Proc. Biochem. Soc. (London), 110: 54-55.
48. Lloyd, A.G., Embery, G., and Fowler, L.J. 1971. Studies on heparin degradation. I. Preparation of [35S]sulphamate derivatives for studies on heparin degrading enzymes of mammalian origin. Biochem. Pharmacol. 20: 637-648.
49. Loganathan, D., Wang, H.M., Mallis, L.M., and Linhardt, R.J. 1991. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry, 29: 4362-4368.
50. Lohse, D.L., and Linhardt, R.L. 1992. Purification and characterization of heparin lyases from Flavobacterium heparinum. J. Biol. Chem. 267: 24 347-24 355.
51. Loomis, A. 1961. Distribution and excretion of heparin. Soc. Exp. Biol. Med. 106: 490-492.
52. Mandal, A.K., Lyden, T., and Saklayen, M.G. 1995. Heparin lowers blood pressure: biological and clinical perspectives. Kidney Int. 47: 1017-1022.
53. 125I-heparin for detection of heparin-binding growth factors. Anal. Biochem. 187: 197-201.
54. Nadkarni, V.D. 1996. Directionally immobilized heparin and heparan sulfate: preparation, analysis and applications. Ph.D. thesis. p. 102.
55. Nadkarni, V.D., Toida, T., Van Gorp, C.L., Schubert, R.L., Weiler, J.M., Hansen, K.P., Caldwell, E.E., and Linhardt, R.J. 1996. Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives. Biochem. J. 244: 515-522.
56. Rice, K., Rottink, M.K., and Linhardt, R. 1987. Fractionation of heparin derived oligosaccharides by gradient polyacrylamide gel electrophoresis. Biochem. J. 244: 515-522.
57. Rivera, T.M., Leone-Bay, A., Paton, D.R., Leipold, H.R., and Baughman, R.A. 1997. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm. Res. 14: 1830-1833.
58. Samama, M.M. 1995. Laboratory monitoring of unfractionated heparin treatment. Clin. Lab. Med. 15: 109-117.
59. Santiago, N., Rivera, T., Mayer, E., and Milstein, S. 1991. Proteinoid microspheres for the oral delivery of heparin. Proc. Int. Symp. Controlled Release Bioact. Mater. 19: 514-515.
60. Steel, R.G.D., and Torrie, J.H. 1980. Principles and procedures of statistics. McGraw Hill Book Co., New York. pp. 599-603.
61. Sue, T.K., Jaques, L.B., and Yuen, E. 1976. Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract. Can. J. Physiol. Pharmacol. 54: 613-617.
62. Toida, T., Yoshida, H., Toyoda, H., Koshishi, I., Imanari, T., Hileman, R.E., Fromm, J.R., and Linhardt, R.J. 1997. Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem. J. 322: 499-506.
63. Turnbull, J.E., and Gallagher, J.T. 1988. Oligosaccharide mapping of heparan sulphate by polyacrylamide-gradient-gel electrophoresis and electrotransfer to nylon membrane. Biochem. J. 251: 597-608.
64. Vannucchi, S., Pasquali, F., Chiarugi, V., and Ruggiero, M. 1986. Internalization and metabolism of endogenous heparin by cultured endothelial cells. Biochem. Biophys. Res. Commun. 140: 294-301.
65. Walenga, J.M., and Fareed, J. 1997. Current status on new anticoagulant and antithrombotic drugs and devices. Curr. Opin. Pulmon. Med. 3: 291-302.
66. Watanabe, J., Hori, K., Iwamoto, K., and Ozeki, S. 1982. Disposition of tritium-labelled heparin in rats. J. Pharmacobio-Dyn. 5: 627-637.
67. Weitz, J., and Hirsh, J. 1993. New anticoagulant strategies. J. Lab. Clin. Med. 122: 364-373.
68. Windsor, E., and Cronkeim, G.E. 1961. Gastrointestinal absorption of heparin and synthetic heparinoids. Nature (London), 190: 263-264.
69. Zoppetti, G., Caramazza, I., Murakami, Y., and Ohno, T. 1992. Structural requirements for duodenal permeability of heparin-diamine complexes. Biochim. Biophys. Acta, 1156: 92-98.